ArticleCancer cell2025
A first-in-class EGFR-directed KRAS G12V selective inhibitor.
Abstract read
In one paragraph
Article in Cancer cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Discovery of a novel and potent KRASJournal of enzyme inhibition and medicinal chemistry · 2026Article
- Review
- The Role of KRAS in Non-Small Cell Lung Cancer: From Molecular Background to Precision Medicine.International journal of molecular sciences · 2026Review
- KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target.Current oncology (Toronto, Ont.) · 2026Review
- Pharmacokinetic/Pharmacodynamic Translation and Model-Informed Drug Development for Oligonucleotide Therapeutics.Journal of clinical pharmacology · 2026Review
- KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion.Apoptosis : an international journal on programmed cell death · 2026Article
- RAS Inhibitors: Changing the Paradigm from the Undruggable.Pharmaceutics · 2026Review
- Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.Expert opinion on drug discovery · 2026Review
- RAS signaling in lung adenocarcinoma is defined by lineage context and DUSP4 loss.JCI insight · 2026Article
- Article
- Systematic and precise interventions for KRAS-mutant cancers.Experimental hematology & oncology · 2026Review
- High prevalence ofPleura and peritoneum · 2026Article
- KRAS Inhibition in Pancreatic Ductal Adenocarcinoma.Journal of clinical medicine · 2026Review
- Small Interfering RNA (siRNA) as a Targeted Therapy for Acute Respiratory Distress Syndrome: Evidence from Experimental Models.International journal of molecular sciences · 2026Review
- Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond.Therapeutic advances in medical oncology · 2026Review
- Unravelling Resistance: Integrating Metabolism, Epigenetics, Immunology, and Proteostasis in Strategies against Kirsten Rat Sarcoma Viral Oncogene Homolog-mutant Colorectal Cancer.International journal of biological sciences · 2026Review
- Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers.The Journal of clinical investigation · 2025Article
- Dendritic siRNA conjugate riding albumin for targeted delivery to solid tumors.Molecular therapy. Nucleic acids · 2025Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Lyla J StanlandEnFuego Therapeutics, Inc, Morrisville, NC 27560, USA.
Hayden P HugginsEnFuego Therapeutics, Inc, Morrisville, NC 27560, USA; Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Snehasudha S SahooLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA.
Alessandro PorrelloLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA.
Yogitha ChareddyLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA; Curriculum in Genetics and Molecular Biology, UNC at Chapel Hill, Chapel Hill, NC, USA.
Salma H AzamLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Jillian L PerryLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; Center for Nanotechnology in Drug Delivery, Chapel Hill, NC, USA; Division of Chemical Biology and Medicinal Chemistry, UNC at Chapel Hill, Chapel Hill, NC, USA.
Pradeep S PallanDepartment of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA.
Kristina WhatelyLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA.
Lincy EdattLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA.
William D GreenLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, UNC at Chapel Hill, Chapel Hill, NC, USA.
Matthew C FlemingDivision of Chemical Biology and Medicinal Chemistry, UNC at Chapel Hill, Chapel Hill, NC, USA; Center for Integrative Chemical Biology and Drug Discovery, Chapel Hill, NC, USA.
Jonah ImEnFuego Therapeutics, Inc, Morrisville, NC 27560, USA; Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Christina Gutierrez-FordLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Imani SimmonsLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Alyaa DawoudLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA.
Katherine I ZhouLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA; Division of Medical Oncology, Duke University, Durham, NC 27705, USA.
Vandanaa JayaprakashEnFuego Therapeutics, Inc, Morrisville, NC 27560, USA; Lineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
Rani S SellersDepartment of Pathology and Laboratory Medicine, UNC at Chapel Hill, Chapel Hill, NC, USA.
Gabriela de la CruzDepartment of Pathology and Laboratory Medicine, UNC at Chapel Hill, Chapel Hill, NC, USA.
Albert WielgusDepartment of Pathology and Laboratory Medicine, UNC at Chapel Hill, Chapel Hill, NC, USA.
Justin MilnerLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, UNC at Chapel Hill, Chapel Hill, NC, USA.
Martin EgliDepartment of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA.
Albert A BowersLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA; Division of Chemical Biology and Medicinal Chemistry, UNC at Chapel Hill, Chapel Hill, NC, USA; Center for Integrative Chemical Biology and Drug Discovery, Chapel Hill, NC, USA; Department of Chemistry, UNC at Chapel Hill, Chapel Hill, NC, USA.
Chad V PecotLineberger Comprehensive Cancer Center, University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; RNA Discovery Center, UNC at Chapel Hill, Chapel Hill, NC, USA; Division of Hematology/Oncology, UNC at Chapel Hill, Chapel Hill, NC, USA. Electronic address: pecot@email.unc.edu.
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MWomen's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3MTRANSFUSION MEDICINE AND RELATED AREAST32HL007057 · NHLBI · DUKE UNIVERSITY · PI Gowthami M Arepally · 1985 to 2026
$10.6MUNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation CenterUG1CA233333 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, MERKER, JASON DEREK · 2019 to 2025
$4.8MMIRA Equipment SupplementR35GM125005 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Albert A Bowers · 2017 to 2026
$3.9MTumor Endothelial Cell Regulation of Pro-Metastatic Fibrin MatricesR01CA258451 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUDLEY, ANDREW CARL, PECOT, CHAD V · 2021 to 2025
$2.9MLigand-Directed KRAS G12V Mutant-Specific TherapeuticsR44CA284932 · NCI · ENFUEGO THERAPEUTICS INC. · PI PECOT, CHAD V, STANLAND, LYLA · 2023 to 2025
$2.1MImmune Regulation of Lung Squamous MetastasisR01CA215075 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PECOT, CHAD V · 2017 to 2021
$2.0MCircle RNA Regulation of Lung Cancer MetastasisR01CA279532 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Chad V Pecot · 2023 to 2026
$1.5MDevelopment of EFTX-001 to target KRAS mutations in cancerR41CA246848 · NCI · ENFUEGO THERAPEUTICS INC. · PI PECOT, CHAD V · 2020 to 2020
$225kNCI NIH HHS P30 CA014236NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA215075NCI NIH HHS R01 CA258451NCI NIH HHS R01 CA279532NCI NIH HHS R41 CA246848NCI NIH HHS R44 CA284932NCI NIH HHS UG1 CA233333NHLBI NIH HHS T32 HL007057NIEHS NIH HHS P30 ES010126NIGMS NIH HHS R35 GM125005
Abstract
Despite KRAS
Indexed as
Antineoplastic AgentsErbB ReceptorsNeoplasmsProto-Oncogene Proteins p21(ras)RNA, Small InterferingAnimalsCell Line, TumorFemaleHumansMiceMice, NudeMutationRNA InterferenceXenograft Model Antitumor AssaysAntineoplastic AgentsEGFR protein, humanErbB ReceptorsKRAS protein, humanProto-Oncogene Proteins p21(ras)RNA, Small InterferingangiogenesiscancerEGFRKRASligand conjugationlung cancermutant-selectiveRNA interferencesiRNAsiRNA delivery
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.